313 related articles for article (PubMed ID: 33785920)
1. It's time to consider a patent reprieve for COVID vaccines.
Nature; 2021 Apr; 592(7852):7. PubMed ID: 33785920
[No Abstract] [Full Text] [Related]
2. Why a pioneering plan to distribute COVID vaccines equitably must succeed.
Nature; 2021 Jan; 589(7841):170. PubMed ID: 33442047
[No Abstract] [Full Text] [Related]
3. Challenges in the rollout of COVID-19 vaccines worldwide.
Burki TK
Lancet Respir Med; 2021 Apr; 9(4):e42-e43. PubMed ID: 33684355
[No Abstract] [Full Text] [Related]
4. Just allocation of COVID-19 vaccines.
Herlitz A; Lederman Z; Miller J; Fleurbaey M; Venkatapuram S; Atuire C; Eckenwiler L; Hassoun N
BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33589419
[No Abstract] [Full Text] [Related]
5. Why Oxford's positive COVID vaccine results are puzzling scientists.
Callaway E
Nature; 2020 Dec; 588(7836):16-18. PubMed ID: 33230278
[No Abstract] [Full Text] [Related]
6. The COVID vaccine challenges that lie ahead.
Nature; 2020 Nov; 587(7835):522. PubMed ID: 33235368
[No Abstract] [Full Text] [Related]
7. Are rich nations up for drug reform?
Check E
Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
[No Abstract] [Full Text] [Related]
8. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
9. Coordinating COVID-19 vaccine deployment through the WHO COVID-19 Partners Platform.
Yu MA; Shen AK; Ryan MJ; Boulanger LL
Bull World Health Organ; 2021 Mar; 99(3):171-171A. PubMed ID: 33716336
[No Abstract] [Full Text] [Related]
10. Is there light at the end of the Covid-19 tunnel?
Mortimer PP
Rev Med Virol; 2021 May; 31(3):e2173. PubMed ID: 33002254
[No Abstract] [Full Text] [Related]
11. Could mixing COVID vaccines boost immune response?
Ledford H
Nature; 2021 Feb; 590(7846):375-376. PubMed ID: 33547431
[No Abstract] [Full Text] [Related]
12. If a coronavirus vaccine arrives, can the world make enough?
Khamsi R
Nature; 2020 Apr; 580(7805):578-580. PubMed ID: 32273621
[No Abstract] [Full Text] [Related]
13. The case for compulsory licensing during COVID-19.
Wong H
J Glob Health; 2020 Jun; 10(1):010358. PubMed ID: 32509289
[No Abstract] [Full Text] [Related]
14. How to redesign COVID vaccines so they protect against variants.
Callaway E; Ledford H
Nature; 2021 Feb; 590(7844):15-16. PubMed ID: 33514888
[No Abstract] [Full Text] [Related]
15. Licensing IP to ensure accessibility to vaccines and other immunisation-related products.
Mehta JM
Vaccine; 2001 Feb; 19(13-14):1581-7; discussion 1592-3. PubMed ID: 11166878
[No Abstract] [Full Text] [Related]
16. Enhancing the WHO's Proposed Framework for Distributing COVID-19 Vaccines Among Countries.
Emanuel EJ; Luna F; Schaefer GO; Tan KC; Wolff J
Am J Public Health; 2021 Mar; 111(3):371-373. PubMed ID: 33566663
[No Abstract] [Full Text] [Related]
17. Survival of the Wealthiest?
Garfinkel M; Sansonetti PJ; Pulverer B
EMBO J; 2020 Dec; 39(23):e107227. PubMed ID: 33205839
[TBL] [Abstract][Full Text] [Related]
18. Novavax offers first evidence that COVID vaccines protect people against variants.
Callaway E; Mallapaty S
Nature; 2021 Feb; 590(7844):17. PubMed ID: 33510489
[No Abstract] [Full Text] [Related]
19. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
So AD; Woo J
BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
[TBL] [Abstract][Full Text] [Related]
20. Ending this pandemic and securing the future.
Clark H; Sirleaf EJ
BMJ; 2021 Nov; 375():n2914. PubMed ID: 34840133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
